Poolbeg Pharma (LON:POLB) Receives House Stock Rating from Shore Capital

Shore Capital reiterated their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a research report sent to investors on Friday, Marketbeat.com reports.

Poolbeg Pharma Trading Up 1.0%

LON:POLB opened at GBX 3.89 on Friday. Poolbeg Pharma has a 12 month low of GBX 2.25 and a 12 month high of GBX 9.68. The stock has a market capitalization of £27.12 million, a price-to-earnings ratio of -335.34 and a beta of 2.11. The firm has a fifty day simple moving average of GBX 3.33 and a two-hundred day simple moving average of GBX 3.10.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).